DLD Asset Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-100,559
Closed -$1.05M 491
2026
Q1
$1.05M Hold
100,559
0.1% 147
2025
Q4
$1.04M Sell
100,559
-13,113
-12% -$135K 0.08% 170
2025
Q3
$1.17M Sell
113,672
-75,050
-40% -$770K 0.08% 147
2025
Q2
$1.92M Sell
188,722
-161,278
-46% -$1.63M 0.16% 99
2025
Q1
$3.51M Buy
+350,000
New +$3.5M 0.27% 48

Other funds holding DMAA

DLD Asset Management's DMAA Position: Q2 2026 in Review

DLD Asset Management sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 100,559 shares — an estimated $1.05M sold.

DLD Asset Management first reported a position in DMAA in Q1 2025 and held it in 5 quarters. The position peaked at $3.51M in Q1 2025. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • DLD Asset Management reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
  • DLD Asset Management sold 100,559 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $1.05M.
  • DLD Asset Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 5 quarters.
  • DLD Asset Management's Drugs Made In America Acquisition Corp position peaked at $3.51M in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on DLD Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.